Open AccessDTX3L is upregulated in glioma and is associated with glioma progression
Author(s) -
Peng Xu,
Xuelei Tao,
Chengjin Zhao,
Qiyu Huang,
Hao Chang,
Na Ban,
Yuanqi Bei,
Xiaojie Xia,
Chaoyan Shen,
Kun Wang,
Li Xu,
Peizhang Wu,
Jianbing Ren,
Donglin Wang
Publication year - 2017
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2017.3023
Subject(s) - glioma , oncogene , cancer research , cell cycle , molecular medicine , malignancy , immunohistochemistry , biology , gene knockdown , apoptosis , carcinogenesis , downregulation and upregulation , pathology , cancer , medicine , immunology , gene , biochemistry , genetics
Gliomas are the most common primary brain tumors of the central nervous system (CNS). Due to the poor prognosis of glioma patients, it is urgent to develop more effective therapies. Deltex-3-like (DTX3L), also known as B-lymphoma and BAL-associated protein (BBAP), has been reported to play an important role in the progression of many tumors. This study aimed to investigate the clinical significance and biological function of DTX3L in human glioma. Clinically, the protein expression level of DTX3L is increased in glioma tissues compared with that observed in normal brain tissues. Immunohistochemical analysis demonstrated that DTX3L was highly expressed in the glioma tissues and its level was correlated with the grade of malignancy. Multivariate analysis revealed the association between high expression of DTX3L and the poor prognosis of glioma patients. In addition, knockdown of DTX3L by siRNA transfection increased glioma cell apoptosis. Moreover, suppression of DTX3L expression was shown to significantly inhibit the migration and invasion of glioma cells. These data indicate that DTX3L plays an important role in the pathogenic process of glioma, suggesting that DTX3L could be a potential prognostic biomarker for glioma.